Nektar Therapeutics Net Income per Employee (NKTR), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Nektar Therapeutics  (NASDAQ: NKTR)
 

Nektar Therapeutics Net Income per Employee

NKTR's Quarterly Results, Trends, Rankings, Statistics
Nektar Therapeutics recorded a cumulative net loss of $-157 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 370 other companies achieving higher income per employee. While Nektar Therapeutics's total ranking has deteriorated compared to the previous quarter from 3999 to 4007.


What is Income per Employee Ratio?






NKTR Net Income per Employee (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,494,079 -2,509,492 -2,604,381 -1,916,444 -1,940,810
NKTR's Total Ranking # 4007 # 3999 # 3698 # 2222 # 2467
Seq. Net Income Change - - - - -


NKTR Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 371
Healthcare Sector # 809
Overall Market # 4007

Net Income per Employee Statistics
High Average Low
$ 14,328,778 $ -2,530,352 $ -8,330,349
(Jun 30 2018)   (Jun 30 2022)







Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-08-18T17:26:20+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.